Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Italy.
Institute of Chemical-Physical Processes (IPCF)-CNR, Messina, Italy.
Spectrochim Acta A Mol Biomol Spectrosc. 2017 Dec 5;187:15-22. doi: 10.1016/j.saa.2017.06.020. Epub 2017 Jun 15.
Current methods for identifying neoplastic cells and discerning them from their normal counterparts are often nonspecific and biologically perturbing. Here, we show that single-cell micro-Raman spectroscopy can be used to discriminate between resistant and sensitive multiple myeloma cell lines based on their highly reproducible biomolecular spectral signatures. In order to demonstrate robustness of the proposed approach, we used two different cell lines of multiple myeloma, namely MM.1S and U266B1, and their counterparts MM.1R and U266/BTZ-R subtypes, resistant to dexamethasone and bortezomib, respectively. Then, micro-Raman spectroscopy provides an easily accurate and noninvasive method for cancer detection for both research and clinical environments. Characteristic peaks, mostly due to different DNA/RNA ratio, nucleic acids, lipids and protein concentrations, allow for discerning the sensitive and resistant subtypes. We also explored principal component analysis (PCA) for resistant cell identification and classification. Sensitive and resistant cells form distinct clusters that can be defined using just two principal components. The identification of drug-resistant cells by confocal micro-Raman spectroscopy is thus proposed as a clinical tool to assess the development of resistance to glucocorticoids and proteasome inhibitors in myeloma cells.
目前识别肿瘤细胞并将其与正常细胞区分开来的方法通常是非特异性的，并且会对生物系统造成干扰。在这里，我们展示了单细胞微拉曼光谱技术可以根据其高度可重复的生物分子光谱特征来区分耐药和敏感的多发性骨髓瘤细胞系。为了证明所提出方法的稳健性，我们使用了两种不同的多发性骨髓瘤细胞系，即 MM.1S 和 U266B1，以及它们对应的耐药地塞米松和硼替佐米的 MM.1R 和 U266/BTZ-R 亚型。然后，微拉曼光谱技术为研究和临床环境中的癌症检测提供了一种简单、准确且非侵入性的方法。特征峰主要归因于不同的 DNA/RNA 比、核酸、脂质和蛋白质浓度，可用于区分敏感和耐药亚型。我们还探索了用于耐药细胞识别和分类的主成分分析 (PCA)。敏感和耐药细胞形成明显的聚类，仅使用两个主成分即可定义这些聚类。因此，通过共聚焦微拉曼光谱术来识别耐药细胞被提议作为一种临床工具，用于评估骨髓瘤细胞对糖皮质激素和蛋白酶体抑制剂的耐药性发展。
